Abstract
The general view on cysteine cathepsins, which were long believed to be primarily involved in intracellular protein turnover, has dramatically changed in last 10 to 15 years. The discovery of new cathepsins, such as cathepsins K, V, X, F and O, and their tissue distribution suggested that at least some of them are involved in very specific cellular processes. Moreover, gene ablation experiments revealed that cathepsins play a vital role in numerous physiological processes, such as antigen processing and presentation, bone remodelling, prohormone processing and wound healing. Their involvement in several pathologies, including osteoporosis, rheumatoid arthritis, osteoarthritis, bronchial asthma and cancer have also been confirmed and today several of them have been validated as relevant targets for therapies. Compounds targeting cathepsins S and K are already in clinical evaluation, whereas others are in experimental phases. The cathepsin K inhibitor AAE-581 (balicatib) as the most advanced of them passed Phase II clinical trials in 2005. In this review, we discuss the current view on cathepsins as an emerging group of targets for several diseases and the development of cathepsin K and S inhibitors for treatment of osteoporosis and various immune disorders.
Keywords: Carboxypeptidases cathepsins B, Apoptosis, cancer biology, Tumour Angiogenesis, extracellular matrix (ECM), MHC Class II Antigen
Current Pharmaceutical Design
Title: Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets
Volume: 13 Issue: 4
Author(s): Olga Vasiljeva, Thomas Reinheckel, Christoph Peters, Dusan Turk, Vito Turk and Boris Turk
Affiliation:
Keywords: Carboxypeptidases cathepsins B, Apoptosis, cancer biology, Tumour Angiogenesis, extracellular matrix (ECM), MHC Class II Antigen
Abstract: The general view on cysteine cathepsins, which were long believed to be primarily involved in intracellular protein turnover, has dramatically changed in last 10 to 15 years. The discovery of new cathepsins, such as cathepsins K, V, X, F and O, and their tissue distribution suggested that at least some of them are involved in very specific cellular processes. Moreover, gene ablation experiments revealed that cathepsins play a vital role in numerous physiological processes, such as antigen processing and presentation, bone remodelling, prohormone processing and wound healing. Their involvement in several pathologies, including osteoporosis, rheumatoid arthritis, osteoarthritis, bronchial asthma and cancer have also been confirmed and today several of them have been validated as relevant targets for therapies. Compounds targeting cathepsins S and K are already in clinical evaluation, whereas others are in experimental phases. The cathepsin K inhibitor AAE-581 (balicatib) as the most advanced of them passed Phase II clinical trials in 2005. In this review, we discuss the current view on cathepsins as an emerging group of targets for several diseases and the development of cathepsin K and S inhibitors for treatment of osteoporosis and various immune disorders.
Export Options
About this article
Cite this article as:
Vasiljeva Olga, Reinheckel Thomas, Peters Christoph, Turk Dusan, Turk Vito and Turk Boris, Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets, Current Pharmaceutical Design 2007; 13 (4) . https://dx.doi.org/10.2174/138161207780162962
DOI https://dx.doi.org/10.2174/138161207780162962 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Relevance of Biased Signaling at the Angiotensin II Type 1 Receptor
Endocrine, Metabolic & Immune Disorders - Drug Targets A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Sudden Unexplained Death in Infancy and Long QT Syndrome
Current Pediatric Reviews Targeting Myocardial Metabolism for the Treatment of Stable Angina
Current Pharmaceutical Design Recent Advances in Image-Based Stem-Cell Labeling and Tracking, and Scaffold-Based Organ Development in Cardiovascular Disease
Recent Patents on Medical Imaging Simultaneous Spectrophotometric Determination of Iron (III) and Vanadium (V) in Water Samples Using a Combination of Partial Least Squares Regression and Solid Phase Extraction with Modified Octadecyl Silica Membrane Disks
Current Analytical Chemistry Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
Recent Advances in Cardiovascular Drug Discovery (Discontinued) A Review on the Sex Differences in Organ and System Pathology with Alcohol Drinking
Current Drug Abuse Reviews Molecular Signature of Human amniotic Fluid Stem Cells During Fetal Development
Current Stem Cell Research & Therapy Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Anabolic Androgenic Steroid (AAS) Related Deaths: Autoptic, Histopathological and Toxicological Findings
Current Neuropharmacology Dendritic Cell Homeostasis in the Regulation of Self-Reactivity
Current Pharmaceutical Design Drugs Targeting the Canonical NF-κB Pathway to Treat Viral and Autoimmune Myocarditis
Current Pharmaceutical Design Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives
Current Vascular Pharmacology Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy Limitations of Current Antiretroviral Agents and Opportunities for Development
Current Pharmaceutical Design Animal Models Used for the Evaluation of Antiretroviral Therapies
Current HIV Research Neuro-Psychological Pattern in Patients Suffering from Primitive Dilated Cardiomyopathy with Impairment in Executive Function
Current Neurovascular Research Mitochondria-Targeted Drugs
Current Molecular Pharmacology